Dr. Janni on the Benefits of Targeted Therapies for HER2-Positive Breast Cancer

Wolfgang Janni, MD, PhD
Published: Tuesday, Apr 04, 2017



Wolfgang Janni, MD, PhD, University of Ulm, discusses the benefits of HER2-targeted therapies for patients with all stages of HER2-positive breast cancer.

According to Janni, the benefits of HER2-targeted therapies in breast cancer outweigh the adverse events that patients experience.

The most common adverse events that are associated with HER2-targeted treatments include cardiotoxicity and diarrhea, states Janni.
 


Wolfgang Janni, MD, PhD, University of Ulm, discusses the benefits of HER2-targeted therapies for patients with all stages of HER2-positive breast cancer.

According to Janni, the benefits of HER2-targeted therapies in breast cancer outweigh the adverse events that patients experience.

The most common adverse events that are associated with HER2-targeted treatments include cardiotoxicity and diarrhea, states Janni.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x